These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14556608)

  • 1. Assuring the benefits of modern medicine for all Americans.
    Woodcock J
    Healthplan; 2003; 44(5):23-6. PubMed ID: 14556608
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB; Kennedy EM
    Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unfinished business of U.S. drug safety regulation.
    Evans BJ; Flockhart DA
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approvals of old drugs put new pressure on payers.
    Silverman E
    Manag Care; 2011 May; 20(5):30-1. PubMed ID: 21667624
    [No Abstract]   [Full Text] [Related]  

  • 6. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug approval and pharmaceutical pricing.
    Kozma CM
    Manag Care Interface; 2002 Feb; 15(2):65-6. PubMed ID: 11875964
    [No Abstract]   [Full Text] [Related]  

  • 8. Bush tails follow-ons.
    Fox J
    Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA to steer nanotech.
    Fox JL
    Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 13. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 14. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 16. 2009 FDA drug approvals.
    Hughes B
    Nat Rev Drug Discov; 2010 Feb; 9(2):89-92. PubMed ID: 20118952
    [No Abstract]   [Full Text] [Related]  

  • 17. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
    Spencer HM
    Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546
    [No Abstract]   [Full Text] [Related]  

  • 18. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 19. Translation of cancer immunotherapies.
    Mulé JJ; Weber JS
    Nat Med; 2004 Nov; 10(11):1153; author reply 1153-4. PubMed ID: 15516900
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.